CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe

David E. Gilham, Reno Debets, Martin Pule, Robert E. Hawkins, Hinrich Abken

    Research output: Contribution to journalArticlepeer-review


    Recent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the profile of T cell therapy. Concomitantly, general expectations are also raised by these reports, with the natural aspiration to deliver this therapy over a wide range of tumor indications. Chimeric antigen receptors (CARs) endow T cell populations with defined antigen specificities that function independently of the natural T cell receptor and permit targeting of T cells towards virtually any tumor. Here, we review the current clinical application of CAR-T cells and relate clinical efficacy and safety of CAR-T cell trials to parameters considered critical for CAR engineering, classified as the three T's of CAR-T cell manipulation. © 2012 Elsevier Ltd.
    Original languageEnglish
    Pages (from-to)377-384
    Number of pages7
    JournalTrends in molecular medicine
    Issue number7
    Publication statusPublished - Jul 2012


    • Adoptive cell therapy
    • Cancer
    • Chimeric antigen receptor
    • Gene transfer
    • Immunotherapy
    • T cell


    Dive into the research topics of 'CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe'. Together they form a unique fingerprint.

    Cite this